Publications by authors named "Peter Ellmark"

Claim this Profile
A
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform.
Barnabas Nyesiga, Karin Hägerbrand, Laura Varas, Anette Gjörloff Wingren, Mats Ohlin, Peter Ellmark

Drug Deliv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.
Hampus Andersson, Ida Uddbäck, Tova Hermodsson, Mona Celander, Amulya Krishna Shetty, Peter Ellmark

Cancer Immunol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.
Songul Kucukcelebi, Freek R van 't Land, Sjoerd H van der Burg, Ferry A L M Eskens, Marjolein Y V Homs, Peter Ellmark

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, Teresa Macarulla Mercade, Aurélien Lambert, Peter Ellmark

Cell Rep Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
Ana Carneiro, Amanda Hahn, Peter Ellmark, Karin Enell Smith, Lena Schultz

J Immunother Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Peter Ellmark

Lancet Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation CD40 agonists for cancer immunotherapy.
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Peter Ellmark

Expert Opin Biol Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.
Viktor Sincic, Ken F Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Peter Ellmark

Cells· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Karin Enell Smith, Sara Fritzell, Anneli Nilsson, Karin Barchan, Anna Rosén, Peter Ellmark

Cancer Immunol Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody.
Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Peter Ellmark

Cells· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Michelle H Nelson, Sara Fritzell, Robert Miller, Doreen Werchau, Danielle Van Citters, Peter Ellmark

Mol Cancer Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Karin Hägerbrand, Laura Varas, Adnan Deronic, Barnabas Nyesiga, Anette Sundstedt, Peter Ellmark

J Immunother Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional profiling demonstrates altered characteristics of CD8 cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.
Milad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, Carl Sandén, Alar Aab, Peter Ellmark

Cancer Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Karin Enell Smith, Peter Ellmark

Cancer Immunol Immunother· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén, Peter Ellmark

Expert Opin Biol Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD137 (4-1BB) costimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, Maite Alvarez, José Medina-Echeverz, Peter Ellmark

Nat Commun· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Peter Ellmark

Oncoimmunology· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.
Sandra M M Irenaeus, Dorte Nielsen, Peter Ellmark, Jeffrey Yachnin, Adnan Deronic

Int J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Peter Ellmark

J Immunother Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Jonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén, Peter Ellmark

Cancer Immunol Immunother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
Luuk van Hooren, Linda C Sandin, Igor Moskalev, Peter Ellmark, Anna Dimberg

Eur J Immunol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Peter Ellmark, Sara M Mangsbo, Christina Furebring, Per Norlén, Thomas H Tötterman

Cancer Immunol Immunother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Sara M Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Peter Ellmark

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C Sandin, Fredrik Eriksson, Peter Ellmark, Angelica Si Loskog, Thomas H Tötterman

Oncoimmunology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Linda C Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Vladimir Tolmachev

Cancer Immunol Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis